ライフサイエンスコーパス: drug target

1 an the mitochondrial ribosome as the primary drug target.

2 ed in numerous cancers making it a potential drug target.

3 age response and is an attractive anticancer drug target.

4 other types of cancer, making it a promising drug target.

5 anism, and it is also of interest as a novel drug target.

6 isease, making it a promising cardiovascular drug target.

7 ision, and as such, it is a broad anticancer drug target.

8 n involved in hemozoin formation, as a novel drug target.

9 volution and favors LigA as an antibacterial drug target.

10 eases and led to identification of Ezh2 as a drug target.

11 ctor within the top GO term, and a potential drug target.

12 g factor PfCPSF3 as a promising antimalarial drug target.

13 can recognition is an important antifibrotic drug target.

14 of inhibitors of FadD32, a highly promising drug target.

15 al of this isozyme as a prognosis marker and drug target.

16 de a platform toward understanding TDP2 as a drug target.

17 has therefore attracted attention as a novel drug target.

18 nels as part of the disease process and as a drug target.

19 betes, and has received great attention as a drug target.

20 beta2)2 nAChR, is an important and promising drug target.

21 eage whose survival no longer depends on the drug target.

22 by offering a potential and species-specific drug target.

23 g efflux we suggest that CsrA is a potential drug target.

24 able therapeutic targeting of this potential drug target.

25 ent of p53 status underlining its value as a drug target.

26 irus, and hence it can serve as an important drug target.

27 onses and serves as an important category of drug targets.

28 siological processes, making GPCRs prominent drug targets.

29 anosomatid ribosome assembly offer potential drug targets.

30 um falciparum have long been investigated as drug targets.

31 ylation of CDK1 and are considered potential drug targets.

32 her enzymes previously viewed as intractable drug targets.

33 groups and lead to the identification of new drug targets.

34 on the identification and validation of the drug targets.

35 thylated genes and 49 genes as antipsychotic drug targets.

36 bout molecular pathophysiology and potential drug targets.

37 euroinflammation, rendering them interesting drug targets.

38 have engendered very high interest as future drug targets.

39 e historically the most successful family of drug targets.

40 of novel biomarkers, disease mechanisms, and drug targets.

41 s of senescent cells and developing specific drug targets.

42 -finding strategies or when prioritize among drug targets.

43 ological responses, therefore are attractive drug targets.

44 ual proteins but also for identifying useful drug targets.

45 ug-target interactions on both ARs and other drug targets.

46 ino acid biosynthetic pathways as future Mtb drug targets.

47 ortunities to discover new parasite-specific drug targets.

48 ifying cryptic sites could expand the set of drug targets.

49 ies potential anticryptococcal or antifungal drug targets.

50 dentifying novel disease genes and potential drug targets.

51 eptors and constitute about 50% of all known drug targets.

52 thogenesis and a test model system for novel drug targets.

53 SRSF proteins are known drug targets.

54 present one of the most important classes of drug targets.

55 chemotypes capable of modulating unexploited drug targets.

56 n and reveals novel potential protein kinase drug targets.

57 represents a useful strategy to uncover new drug targets.

58 ume and that these genes represent important drug targets.

59 chaperones might be potential candidates for drug targets.

60 pinning these diseases and suggest potential drug targets.

61 and represent one of the largest families of drug targets.

62 , from cancer-causing mutations to drugs and drug targets.

63 iological pathways and reveal possible novel drug targets.

64 our continuous search for novel antimalarial drug targets.

65 re of considerable interest as antibacterial drug targets.

66 identify disease genes, genetic modules and drug targets.

67 10, IL-18, and IL-12 p40, and identified 140 drugs targeting 16 of them.

68 nd multiple mutant strains, (2) can identify drug targets, (3) detects not only essential genes, but

69 The only marketed drug targeting a PAR is vorapaxar, a selective antagonis

70 py cancer cells are effectively treated with drugs targeting acquired phenotypes.

71 utic strategies and identify novel drugs and drug targets across multiple cancer types.

72 drugs in a DESS score that is based on known drug-target activity profiles.

73 target electrostatics are validated against drug-target affinity data, yielding superior computation

74 phosphatase has been proposed as a potential drug target against Leishmania parasites that cause up t

75 n cysteine protease cathepsin B, a potential drug target and prognostic marker for tumor metastasis.

76 iomarkers are used as surrogate measures for drug targeting and approval and are generally based on p

77 a membrane-protein-supporting platform, or a drug targeting and delivery vehicle in general, is under

78 membrane protein functions, or involved with drug targeting and delivery.

79 human liver and lung, including hundreds of drug targets and disease genes.

80 Databases collecting drug targets and gene annotations are growing and can be

81 Identification of drug targets and mechanism of action (MoA) for new and u

82 Genetic variants in drug targets and metabolizing enzymes often have importa

83 tin-like phospholipases are likely effective drug targets and progress in the tools available to the

84 celerate the identification of antimicrobial drug targets and resistance mechanisms.

85 eeded as more relevant tools to identify new drug targets and therapies.

86 face proteins, representing a major class of drug targets and thus playing an important role in nucle

87 Investigations into novel bacterial drug targets and vaccines are necessary to overcome tube

88 nal information about the characteristics of drugs, targets and DTIs, such as chemical structure, gen

89 the N-terminal region of NHR trimer as a new drug target, and then we designed several short artifici

90 e recognized importance of these proteins as drug targets, and although the pharmaceutical industry h

91 volanesorsen, a second-generation antisense drug targeting apoC-III, were determined in 2 human inte

92 eveloping, testing, and ultimately improving drugs targeting AR.

93 Few known malaria drug targets are expressed in quiescent parasites, but p

94 cantly, its underlying biology and potential drug targets are still unexplored.

95 501 chemical-protein interactions for human drug targets, as drawn from the DrugBank database.

96 proposed method shows promising results for drug-target association prediction: 98.96% AUC ROC score

97 d in similarity-based methods for predicting drug-target associations based on the array of varying f

98 riant in TNFSF13B, encoding the cytokine and drug target B-cell activating factor (BAFF), was associa

99 These data imply an efficacy of drugs targeting BAT to treat metabolic disease that is a

100 therapies may profit from combinations with drugs targeting BCR(-) tumour cells.

101 This process is an attractive drug target because cleavage of concatemeric DNA is not

102 It has become an attractive drug target because its inhibition may provide significa

103 received considerable attention as potential drug targets because of their ability to modulate Galpha

104 topoisomerases are attractive antibacterial drug targets because of their importance in bacterial gr

105 r cell mitochondria are promising anticancer drug targets because they control cell death and are str

106 At the same time, the importance of drug-target binding kinetics is growing since the kineti

107 is changes in the amino acids that form the drug-target binding site.

108 biological predisposition and are potential drug targets) brought to the fore APOE and IL6 from amon

109 gene expression programs and is an emerging drug target, but its oncogenic role is unclear.

110 riptional regulators and have emerged as new drug targets, but their functional distinction has remai

111 are increasingly being explored as potential drug targets, but their potent and specific inhibitors a

112 Drugs targeting calcineurin are potent antifungal agents

113 ources including databases containing drugs, drug targets, chemical structures, protein-ligand struct

114 Further investigation of drugs targeting chromatin regulators is warranted in HPV

115 if slows the rate of formation for the final drug-target complex by up to 3 orders of magnitude.

116 If the drug-target complex dissociates rapidly, the antibiotic

117 a clear example in which the lifetime of the drug-target complex is controlled by interactions in the

118 d to rationally modulate the lifetime of the drug-target complex.

119 st class of both human membrane proteins and drug targets-depends critically on their ability to chan

120 e accelerated the identification of putative drug targets derived from the nematode nervous system.

121 The application of drugs targeting different convulsant mechanisms (4-Amino

122 pe effects for the reaction catalyzed by the drug target dihydrofolate reductase and established that

123 rs of PKR should be used in combination with drugs targeting directly the inflammasome.

124 nal nanomaterials and the design of anti-HIV drugs targeting (dis)assembly and biocompatible nanocoat

125 Finally, slow drug-target dissociation and slow diffusion out of cells

126 The ability to directly image and quantify drug-target engagement and drug distribution with subcel

127 clinical response was associated with taxane drug-target engagement, evidenced by decreased percent a

128 r antibody imaging can potentially elucidate drug target expression, tracer uptake in the tumor, tumo

129 nase DDR1 (discoidin domain receptor 1) is a drug target for a wide range of human diseases, but the

130 Thus, miR-17 family is a promising drug target for ADPKD, and miR-17-mediated inhibition of

131 rafish, MAP2K5 kinase emerged as a potential drug target for ALS therapy.

132 mine synthesis capacity as a potential novel drug target for bipolar disorder and schizophrenia.

133 lpha pathway should be further explored as a drug target for bone diseases.

134 The epigenomic reader Brd4 is an important drug target for cancers.

135 n Protein Tyrosine Phosphatase 1B (PTP1B), a drug target for diabetes and cancer that catalyzes the d

136 h the GLP-1 receptor (GLP-1R) is a validated drug target for diabetes, the importance of the GIP rece

137 Hence, T-channels may be a promising new drug target for different cognitive deficits.

138 kinase as an oncogenic driver and candidate drug target for FL-HCC, and establishes a practical mode

139 se the STYX-FBXW7 interaction as a promising drug target for future investigations.

140 regulator of the Hh pathway and a potential drug target for Hh-driven cancers.

141 and we therefore studied their potential as drug target for influenza.

142 Our study identifies Vps34 as a new drug target for insulin resistance in Type-2 diabetes, i

143 ene for human globozoospermia and a possible drug target for male contraception.

144 ignaling regulation, and reveals a potential drug target for modulating Hh signaling activity.

145 The NorA efflux pump is a potential drug target for reversal of resistance to selected antib

146 pro-tumorigenic role makes Cdk5 a promising drug target for the development of new cancer therapies.

147 rs, suggesting that TAAR1 may be a promising drug target for the treatment of cocaine addiction.

148 is a new, unique, and specific biomarker and drug target for the treatment of Ewing sarcoma.

149 3 epoxide-Srcin1 axis presents new potential drug targets for allergic diseases.

150 ein-coupled receptors are the most important drug targets for human diseases.

151 This study establishes the PLKs as potential drug targets for influenza and contributes to a more det

152 Because Hsp70s are emerging as potential drug targets for many diseases, fully mapping an alloste

153 eria and highlights a new class of potential drug targets for mycobacterial diseases.

154 nits KChIP1, KChIP2, and DPP10 are potential drug targets for neuropathic pain because they form a ch

155 or activity, have been suggested to be novel drug targets for neuropathic pain.

156 these modulatory subunits could be potential drug targets for neuropathic pain.SIGNIFICANCE STATEMENT

157 iology in PD risk, and suggest potential new drug targets for PD.

158 es (ROCK1 and ROCK2) are identified as novel drug targets for PSP and CBD.

159 ng-term goal is to establish some of them as drug targets for the development of the next generation

160 identification of diagnostic biomarkers and drug targets for the filarial infection of humans.

161 ic gelsolin signaling pathway, providing new drug targets for the treatment of demyelination diseases

162 these pathways could help to identify novel drug targets for the treatment of schizophrenia.

163 imalarial drug.Protein kinases are promising drug targets for treatment of malaria.

164 ulations, and adding direct regulations to a drug-target generally reduces its druggability.

165 association signals, part of which included drug target genes.

166 At least 30% of all approved drugs target GPCRs; thus, Gpr126 represents an attractiv

167 Drug target identification and elucidation of the mechan

168 addition to the methods available for novel drug target identification and validation.

169 entification), a network analysis method for drug target identification in haploinsufficiency profili

170 ional research, including drug discovery and drug target identification.

171 isease, thus classifying BChE as a promising drug target in advanced Alzheimer's disease.

172 findings indicate that PTGER4 is a potential drug target in AI-resistant cancers.

173 e androgen receptor (AR) is also a potential drug target in breast cancer treatment.

174 rized as a critical oncogene and a promising drug target in human malignant tumors.

175 found to inhibit RNA polymerase, a validated drug target in M. tuberculosis.

176 nsing receptor and represents a possible new drug target in metabolic disorders.

177 indings highlight the relevance of MLL2 as a drug target in MLL-rearranged leukemia and suggest its b

178 in-related protein 1 (Drp1) is an attractive drug target in numerous maladies that range from heart d

179 peptide 1 (GLP-1) make it a potent candidate drug target in the treatment of type 2 diabetes mellitus

180 and humans, and it has become an attractive drug target in type II diabetes.

181 engineering of ligands, enabling studies of drug targeting in animal species and subsequent use in h

182 uble-sgRNAs directed against 21,321 pairs of drug targets in K562 leukemia cells and identified synth

183 Y341 phosphorylation are potential candidate drug targets in selected Ras-dependent cancers.

184 rofiling probes to identify parasite protein drug targets in situ.

185 hy, and predict further efficacious pairs of drug targets in the network through a network-wide combi

186 requirements, essential genes, and candidate drug targets in these strains.

187 Novel drug targets include the bile BA receptors, farnesoid X

188 nd screening of some of the most challenging drug targets including GPCRs.

189 ation of undruggable tumour suppressors with drug targets informs therapeutic options.

190 Identifying drug-target interaction (DTI) candidates is crucial for

191 In silico drug-target interaction (DTI) prediction plays an integr

192 ssion based protein interaction networks and drug-target interaction networks.

193 ment over other state-of-the-art methods for drug-target interaction prediction.

194 balancing and boosting technique to predict drug-target interaction.

195 tion (DNILMF) algorithm to predict potential drug-target interactions (DTI).

196 ly, we outline a novel approach for relating drug-target interactions and potency to discrete motivat

197 ing heterogeneous information to predict new drug-target interactions and repurpose existing drugs.Ne

198 nt and membrane effects, we demonstrate that drug-target interactions are strengthened by pronounced

199 al pipeline, called DTINet, to predict novel drug-target interactions from a constructed heterogeneou

200 computational methods for predictioning new drug-target interactions have gained a tremendous intere

201 Here, we identify a novel mechanism by which drug-target interactions in resistant bacteria can be en

202 Prediction of new drug-target interactions is critically important as it c

203 However, experimental prediction of drug-target interactions is expensive and time-consuming

204 awareness to consider the kinetic aspects of drug-target interactions on both ARs and other drug targ

205 st, a prediction model for identification of drug-target interactions using evolutionary and structur

206 At the molecular level, DrugCentral bridges drug-target interactions with pharmacological action and

207 n of both the thermodynamics and kinetics of drug-target interactions, it follows that the structures

208 functional families can be used to identify drug-target interactions, opening a new research directi

209 Drug resistance mechanisms include altered drug-target interactions, reduced cellular drug concentr

210 these techniques to provide new knowledge on drug-target interactions.

211 chers and practitioners to use it to predict drug-target interactions.

212 surface, which alter the nature of specific drug-target interactions.

213 Evaluation of the BRPF family as a potential drug target is at an early stage although there is an em

214 Each drug target is linked to a disease using integrated geno

215 s, a thorough understanding of key validated drug targets is required.

216 provide critical insights for development of drugs targeting LTA4H.

217 izophrenic patients suggests that additional drug targets may be effective in improving aspects of th

218 anisotropy microscopy acquisition to perform drug-target measurements.

219 rs influencing mortality; with this in mind, drug-targeting mechanisms involved in liver injury shoul

220 Drugs targeting metabotropic glutamate receptor 5 (mGluR

221 disease aetiology and identifying potential drug targets, microbial GWAS are likely to further advan

222 We anticipate that rational development of drugs targeting molecular chaperones might help in futur

223 ted database of paediatric biological tumour drug targets; molecular profiling of all paediatric tumo

224 resents the potential to deliver more potent drugs targeted more specifically to the site(s) of disea

225 omplex network theory to predict DTIs from a drug-target network.

226 may also be needed in patients treated with drugs targeting NTCP.

227 e lipid lysophosphatidic acid (LPA) and is a drug target of considerable interest for numerous pathol

228 e essential core of the glideosome, enabling drug targeting of both of its core components to inhibit

229 Accordingly, any potential drug targeting of this gene product must be strictly ass

230 mals so may be exploited as an antimicrobial drug target or used as a substitute for dysfunctional re

231 dge that has the potential to indicate novel drug targets or markers for personalised medicine.

232 ge is available about the characteristics of drugs, targets, or their interactions.

233 door to the rapid development of additional drugs targeting other disease-associated genes in the sa

234 ion, might be used in combination with other drugs targeting other mechanisms of disease, although ad

235 f cysteine proteases are highly sought-after drug targets owing to their essential roles in apoptosis

236 ukemia cells and identified synthetic lethal drug target pairs for which corresponding drugs exhibit

237 domly select negative samples from unlabeled drug-target pairs, which introduces a lot of false-posit

238 apable of providing a promising solution for drug-target prediction based on topological similarity w

239 ing drugs.Network-based data integration for drug-target prediction is a promising avenue for drug re

240 We propose a similarity-based drug-target prediction method that enhances existing ass

241 ed solutions to provide a flexible method of drug-target prediction.

242 (4) building DNILMF model and smoothing new drug/target predictions based on their neighbors.

243 re consists of four steps: (1) inferring new drug/target profiles and constructing profile kernel mat

244 al genomics, genetic interaction mapping and drug-target profiling in M. tuberculosis.

245 f diseases, protein-protein interactions, or drug target relations, and demonstrate performance that

246 d improved utility for predicting both known drug-target relationships and overall drug sensitivity a

247 logical roles of AMPK and its potential as a drug target remain incompletely understood, largely beca

248 izable for improvements in cellular potency, drug target residence time, and pharmacokinetic paramete

249 Analysis of these data suggests that drug-target residence time (off-rate) may be an importan

250 he cellular thermal shift assay (CETSA), and drug-target residence time was determined via SPR.

251 the important role that on-rates can play in drug-target residence time.

252 id metabolism protein (and a potential azole drug target), respectively.

253 ite interactions, identification of putative drug targets, screening of potential interventions, and

254 ggable CATH functional families, enriched in drug targets, show that relatives exhibit highly conserv

255 hy pathogenesis and as potential therapeutic drug targets.SIGNIFICANCE STATEMENT Neurodegenerative di

256 Drugs targeting such epigenetic mechanisms may open ther

257 y demonstrates glycation constitutes a novel drug target that can be explored in synucleinopathies as

258 strategy and identify Bdf1 as an antifungal drug target that can be selectively inhibited without an

259 Endosomal GPCRs are a drug target that deserve further attention.

260 Overall, our findings provide a novel drug target that may serve as the rationale for the deve

261 chemokine receptor 3 (CXCR3) is a potential drug target that mediates signaling involved in cancer m

262 ion might aid in the identification of novel drug targets that can promote larger hippocampal volumes

263 ponse of MCTS following UNC1999 treatment, a drug targeting the enzymes that catalyze H3K27me3, namel

264 tive treatment with etanercept, a biological drug targeting the TNF pathway and suppressing inflammat

265 the way for the development of new selective drugs targeting the amyloidogenic proteins implicated in

266 be considered in the clinical development of drugs targeting the cytochrome bc1 :aa3 , as well as for

267 of vaccine strategies and the development of drugs targeting the early stages of Hepatitis C virus (H

268 Several drugs targeting the myostatin pathway have been used in

269 The wide range of drugs targeting the serotonergic system could be useful

270 malian cell DNA replication, indicating that drugs targeting the terminase complex could be safe and

271 aripiprazole, and risperidone, and of kinase drugs targeting the VEGF receptor, demonstrates how unde

272 Representing important pharmaceutical drug targets, the corresponding G-protein-coupled recept

273 ist includes a number of known and potential drug targets, the identification of NTP binding can dire

274 Importantly, drugs targeting these GPVI signaling pathways are alread

275 ht reveal the pharmacodynamic (PD) effect of drugs targeting this cancer-specific metabolic pathway.

276 e responsible for parasite transmission, and drugs targeting this stage are needed to support malaria

277 nd thus the potential efficacy of envisioned drugs targeting this tissue to treat metabolic disease.

278 Drug targeting those networks, in combination with BRAF

279 her suggest that PfHDP could be an important drug target to combat malaria.

280 p41 NHR trimer has been known as the classic drug target to develop fusion inhibitors derived from th

281 highlighted the great potential of TCTP as a drug target to enhance conventional chemotherapy for can

282 making serine 14 phosphorylation a potential drug target to interfere with TRPC6 channel activity.

283 ying new disease markers and potential novel drug targets to better define and combat obesity and rel

284 human, suggesting that they may be potential drug targets to block encystation.

285 eported data and will help to identify novel drug targets to combat HIV-1 infection.IMPORTANCE HIV-1

286 ay offer a therapeutically relevant panel of drug targets to correct basic defects in F508del-CFTR pr

287 etylcholine receptors (nAChRs) are promising drug targets to manage several neurological disorders an

288 ens are a powerful way to identify candidate drug targets to specifically kill tumor cells, but this

289 nteracting molecules that could serve as new drug targets to treat APOL1-associated renal diseases.

290 ulin signaling that could serve as potential drug targets to treat type 2 diabetes.

291 lications in identifying protein regions for drug targets, understanding the biological underpinnings

292 However, novel drug target validation is hampered by the absence of ade

293 nterfering with IL-31, a currently evaluated drug target, we will have to consider that low doses of

294 s the MEP pathway's potential as a selective drug target, which is absent in humans but essential to

295 The diverse nAChRs represent distinguishable drug targets with different functions: Knockdown of unc-

296 about the association of known and potential drug targets with diseases.

297 evidence that 5-HT2C receptors are suitable drug targets with fewer side effects, greater therapeuti

298 nhibition of HMG-CoA reductase (the intended drug target) with the same lipids and metabolites for 27

299 onsensus that GR deserves a second life as a drug target, with either refined classic GCs or a novel

300 toyltransferase (NMT) represents a promising drug target within the parasitic protozoa Trypanosoma br